Newsbenzinga
AIM ImmunoTech Announces Final Subjects Receives Last Dose Of Ampligen Under Study Protocol In Phase 2 DURIPANC Clinical Study
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…